{"entity":{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","aka":["TROPION-Lung15"],"tldr":"A phase 3 trial of Datopotamab deruxtecan, Osimertinib, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.","summary":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. ClinicalTrials.gov record last updated 2026-05-14: recruiting. Enrollment is planned at 744 participants. Primary completion is estimated at 2026-09-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin. Registered primary measures: Progression free Survival (PFS).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06417814","url":"https://clinicaltrials.gov/study/NCT06417814"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["trop2"],"drugs":["datopotamab-deruxtecan","osimertinib","pemetrexed","carboplatin","cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-05-14: recruiting. Enrollment is planned at 744 participants. Primary completion is estimated at 2026-09-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06417814","phase":"3","setting":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"AstraZeneca","participation":[{"nct":"NCT06417814","source":"https://clinicaltrials.gov/study/NCT06417814","fetchedAt":"2026-10-07T16:54:39.727Z","studySha256":"634499e80c6ab9ef225c2aaa15b7d4bb4bd3a3b6b31701b01ce62607059a44ec","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-14","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":744,"enrolmentType":"ESTIMATED","siteCount":303,"recruitingSiteCount":267,"countries":["Australia","Belgium","Brazil","Canada","China","France","Germany","Greece","Hong Kong","India","Israel","Italy","Japan","Malaysia","Netherlands","Philippines","Poland","Portugal","Romania","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom","United States","Vietnam"]}],"started":"2024-10-04","startedType":"actual","enrolled":744,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06417814/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"idea":[{"id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/"}]}}